Bringing Accurate and Flexible Prostate Cancer Insights to AUA2025!

MyProstateScore 2.0 (MPS2) is the only biomarker test with a 99% negative predictive value (NPV) for the prediction of Grade Group ≥2 prostate cancer in patients with a previous negative biopsy. Now with the option to collect samples at home and eligible for reimbursement from Medicare, MPS2 provides an enhanced patient experience that fits seamlessly into your workflow.

Come see us at Booth #719 during AUA2025 and discover how a 30-second urine sample offers unparalleled insights to guide your patients through prostate cancer risk assessment.

Schedule a meeting with our team at the event, or connect with us to learn more about MPS2.